文献速递浆细胞疾病造血干细胞移植与细胞治疗

溶瘤麻疹病毒治疗增强多发性骨髓瘤患者肿瘤抗原特异性T细胞应答

Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.
PubMed 文献 · Leukemia · 2020-04-23

研究对10例多发性骨髓瘤患者在全身给予编码钠碘同向转运体的溶瘤麻疹病毒(MV-NIS)前后采集外周血单个核细胞,检测针对已知骨髓瘤肿瘤相关抗原的T细胞应答。基线即可检出针对MAGE-C1和hTERT的T细胞应答;MV-NIS治疗后针对MAGE-C1和MAGE-A3的T细胞应答显著增加(P < 0.05)。

要点

  • 基线即可检出针对MAGE-C1和hTERT的T细胞应答。
  • MV-NIS治疗后针对MAGE-C1和MAGE-A3的T细胞应答显著增加(P < 0.05)。
  • 溶瘤病毒治疗可作为抗原不可知疫苗增强针对肿瘤相关抗原的细胞毒性T淋巴细胞应答。

核心结论

  • 溶瘤病毒治疗可作为抗原不可知疫苗,增强多发性骨髓瘤患者针对肿瘤相关抗原的细胞毒性T淋巴细胞应答,为继续探索该方式联合免疫检查点阻断提供基础。

研究设计与样本

  • 研究纳入10例多发性骨髓瘤患者,在全身给予编码钠碘同向转运体的溶瘤麻疹病毒(MV-NIS)前后采集外周血单个核细胞,检测针对一组已知骨髓瘤肿瘤相关抗原的T细胞应答。

主要发现

  • 尽管患者既往接受过多种免疫抑制性抗骨髓瘤治疗方案,部分肿瘤相关抗原的T细胞应答在麻疹病毒治疗前即可检出。
  • 基线可检出针对MAGE-C1和hTERT的T细胞应答。
  • MV-NIS治疗显著增加针对MAGE-C1和MAGE-A3的T细胞应答(P < 0.05)。
  • 一例在MV-NIS治疗后达到完全缓解的患者,基线时对麻疹病毒蛋白和十种受检肿瘤相关抗原中的八种均有强T细胞应答。

临床怎么用

  • 原文结论提出溶瘤病毒治疗可作为抗原不可知疫苗增强针对肿瘤相关抗原的细胞毒性T淋巴细胞应答,为继续探索该方式联合免疫检查点阻断提供基础。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected tumor cells. To investigate whether oncolytic virotherapy can increase immune responses to tumor antigens in human subjects, we studied T-cell responses against a panel of known myeloma TAAs using PBMC samples obtained from ten myeloma patients before and after systemic administration of an oncolytic measles virus encoding sodium iodide symporter (MV-NIS). Despite their prior exposures to multiple immunosuppressive antimyeloma treatment regimens, T-cell responses to some of the TAAs were detectable even before measles virotherapy. Measurable baseline T-cell responses against MAGE-C1 and hTERT were present. Furthermore, MV-NIS treatment significantly (P < 0.05) increased T-cell responses against MAGE-C1 and MAGE-A3. Interestingly, one patient who achieved complete remission after MV-NIS therapy had strong baseline T-cell responses both to measles virus proteins and to eight of the ten tested TAAs. Our data demonstrate that oncolytic virotherapy can function as an antigen agnostic vaccine, increasing cytotoxic T-lymphocyte responses against TAAs in patients with multiple myeloma, providing a basis for continued exploration of this modality in combination with immune checkpoint blockade.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Packiriswamy N, Upreti D, Zhou Y, et al. Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia. 2020. PMID: 32327728. doi:10.1038/s41375-020-0828-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。